Insmed Inc Stock Alpha and Beta Analysis
| INSM Stock | USD 164.87 3.87 2.40% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Insmed Inc. It also helps investors analyze the systematic and unsystematic risks associated with investing in Insmed over a specified time horizon. Remember, high Insmed's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Insmed's market risk premium analysis include:
Beta (0.31) | Alpha (0.21) | Risk 3 | Sharpe Ratio (0.11) | Expected Return (0.33) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Insmed Analysis, Insmed Valuation, Insmed Correlation, Insmed Hype Analysis, Insmed Volatility, Insmed Price History and analyze Insmed Performance. Insmed Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Insmed market risk premium is the additional return an investor will receive from holding Insmed long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Insmed. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Insmed's performance over market.| α | -0.21 | β | -0.31 |
Insmed expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Insmed's Buy-and-hold return. Our buy-and-hold chart shows how Insmed performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Insmed Market Price Analysis
Market price analysis indicators help investors to evaluate how Insmed stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Insmed shares will generate the highest return on investment. By understating and applying Insmed stock market price indicators, traders can identify Insmed position entry and exit signals to maximize returns.
| Price Series Summation | ||
| Price Series Division | ||
| Tanh Of Price Series | ||
| Price Floor Movement | ||
| Plus Directional Indicator | ||
| Rate of change | ||
| Simple Moving Average | ||
| Exponential Moving Average | ||
| Tristar Pattern | ||
| Harami Pattern |
Insmed Return and Market Media
The median price of Insmed for the period between Sat, Nov 22, 2025 and Fri, Feb 20, 2026 is 175.2 with a coefficient of variation of 11.58. The daily time series for the period is distributed with a sample standard deviation of 20.44, arithmetic mean of 176.56, and mean deviation of 17.62. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 5000 shares by Anderson Elizabeth M of Insmed at 204.58 subject to Rule 16b-3 | 11/24/2025 |
2 | Disposition of 8895 shares by Flammer Martina M.d. of Insmed at 25.83 subject to Rule 16b-3 | 12/01/2025 |
3 | Insmed Provides Clinical and Business Update | 12/17/2025 |
4 | Disposition of 4358 shares by Flammer Martina M.d. of Insmed at 19.74 subject to Rule 16b-3 | 01/05/2026 |
5 | Assessing Insmed Valuation After Strong MultiYear Returns And Recent Share Price Pullback | 01/12/2026 |
6 | Disposition of 447 shares by Lewis William of Insmed at 164.24 subject to Rule 16b-3 | 01/16/2026 |
7 | INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM | 01/22/2026 |
8 | Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder at Pulmonary Vascular Research Institute 2026 Congress | 01/28/2026 |
9 | Disposition of 7982 shares by Flammer Martina M.d. of Insmed at 65.72 subject to Rule 16b-3 | 02/02/2026 |
10 | Disposition of 795 shares by Flammer Martina M.d. of Insmed at 155.77 subject to Rule 16b-3 | 02/03/2026 |
11 | Insider Selling Insmed CEO Sells 3,009 Shares of Stock | 02/04/2026 |
12 | Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026 | 02/05/2026 |
13 | Disposition of 4440 shares by Lewis William of Insmed at 17.16 subject to Rule 16b-3 | 02/09/2026 |
14 | Is It Time To Reassess Insmed After The Recent Share Price Pullback | 02/11/2026 |
15 | Insmed To Present at March 2026 Investor Conferences | 02/13/2026 |
16 | 1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today | 02/17/2026 |
17 | A Closer Look at Insmeds Options Market Dynamics | 02/19/2026 |
About Insmed Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Insmed or other stocks. Alpha measures the amount that position in Insmed Inc has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Days Of Sales Outstanding | 49.26 | 52.2 | 84.78 | 48.14 | Days Of Inventory Outstanding | 463.38 | 419.64 | 392.11 | 534.51 |
Insmed Upcoming Company Events
As portrayed in its financial statements, the presentation of Insmed's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Insmed's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Insmed's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Insmed. Please utilize our Beneish M Score to check the likelihood of Insmed's management manipulating its earnings.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Insmed
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Insmed Analysis, Insmed Valuation, Insmed Correlation, Insmed Hype Analysis, Insmed Volatility, Insmed Price History and analyze Insmed Performance. You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Insmed technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.